Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations...
Saved in:
| Published in | PloS one Vol. 11; no. 2; p. e0149722 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
19.02.2016
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases.
This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users.
Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases.
Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases. |
|---|---|
| AbstractList | Background
Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases.
Materials and Methods
This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users.
Results
Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases.
Conclusion
Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases. Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases. This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users. Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases. Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases. Background Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases. Materials and Methods This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users. Results Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases. Conclusion Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases. Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases.BACKGROUNDAntacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases.This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users.MATERIALS AND METHODSThis retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users.Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases.RESULTSFifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases.Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases.CONCLUSIONAntacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases. Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo brain metastases. This retrospective study evaluated 269 patients with EGFR-mutant non-small cell lung cancer (NSCLC) who had been diagnosed between December 2010 and December 2013, and had been treated using first-line first-generation EGFR-TKIs. Among these patients, we identified patients who concurrently used H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) as antacids. Patients who exhibited >30% overlap between the use of TKIs and antacids were considered antacid users. Fifty-seven patients (57/269, 21.2%) were antacid users, and antacid use did not significantly affect progression-free survival (PFS; no antacids: 11.2 months, H2RAs: 9.4 months, PPIs: 6.7 months; p = 0.234). However, antacid use significantly reduced overall survival (OS; no antacids: 25.0 months, H2RAs: 15.5 months, PPIs: 11.3 months; p = 0.002). Antacid use did not affect PFS for various metastasis sites, although antacid users with de novo brain metastases exhibited significantly shorter OS, compared to non-users (11.8 vs. 16.3 months, respectively; p = 0.041). Antacid use did not significantly affect OS in patients with bone, liver, or pleural metastases. Antacid use reduced OS among patients with EGFR-mutant NSCLC who were treated using first-line first-generation EGFR-TKIs, and especially among patients with de novo brain metastases. |
| Audience | Academic |
| Author | Chang, Ya-Chun Su, Mao-Chang Chang, Huang-Chih Lin, Meng-Chih Wang, Chin-Chou Lai, Chien-Hao Liu, Shih-Feng Chen, Yu-Mu Wang, Yi-Hsi Chen, Hung-Chen Fang, Wen-Feng Chung, Yu-Hsiu Chao, Tung-Ying Tseng, Chia-Cheng Huang, Kuo-Tung |
| AuthorAffiliation | 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan H. Lee Moffitt Cancer Center & Research Institute, UNITED STATES 2 Department of Respiratory Care, Chang Gung Institute of Technology, Chiayi, Taiwan |
| AuthorAffiliation_xml | – name: 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan – name: 2 Department of Respiratory Care, Chang Gung Institute of Technology, Chiayi, Taiwan – name: H. Lee Moffitt Cancer Center & Research Institute, UNITED STATES |
| Author_xml | – sequence: 1 givenname: Yu-Mu surname: Chen fullname: Chen, Yu-Mu – sequence: 2 givenname: Chien-Hao surname: Lai fullname: Lai, Chien-Hao – sequence: 3 givenname: Huang-Chih surname: Chang fullname: Chang, Huang-Chih – sequence: 4 givenname: Tung-Ying surname: Chao fullname: Chao, Tung-Ying – sequence: 5 givenname: Chia-Cheng surname: Tseng fullname: Tseng, Chia-Cheng – sequence: 6 givenname: Wen-Feng surname: Fang fullname: Fang, Wen-Feng – sequence: 7 givenname: Chin-Chou surname: Wang fullname: Wang, Chin-Chou – sequence: 8 givenname: Yu-Hsiu surname: Chung fullname: Chung, Yu-Hsiu – sequence: 9 givenname: Yi-Hsi surname: Wang fullname: Wang, Yi-Hsi – sequence: 10 givenname: Mao-Chang surname: Su fullname: Su, Mao-Chang – sequence: 11 givenname: Shih-Feng surname: Liu fullname: Liu, Shih-Feng – sequence: 12 givenname: Kuo-Tung surname: Huang fullname: Huang, Kuo-Tung – sequence: 13 givenname: Hung-Chen surname: Chen fullname: Chen, Hung-Chen – sequence: 14 givenname: Ya-Chun surname: Chang fullname: Chang, Ya-Chun – sequence: 15 givenname: Meng-Chih surname: Lin fullname: Lin, Meng-Chih |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26894507$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk21v0zAQxyM0xB7gGyCwhITgRUqcuHHCC6RRtlHRMbQH9tJynUvrKrWL7WzsM_MluGwZWqcJUKLYOf_uf2f7bjvaMNZAFD2nyYBmnL5b2NYZ2QxWaB4klJU8TR9FW7TM0jhPk2zjznwz2vZ-kSTDrMjzJ9FmmhclGyZ8K_q1a4JUuiJnHog0FfkE5Ku9sOSjk9qQQwjS4wue4N83GTSY4MmlDnOyt9IVuKVsyIGzl2jYlypYR45BwQon8WEbpAkoZ-ITxBoyAvxMWjMjI2kUOHI-t-QcHJBTBzJAl4XG1X3tfIgn2kA_PQADDoNb88-o5PTKWd-5ftEGEydjM9dTjSv-afS4lo2HZ_24E53t752OPseTo4PxaHcSq7xMQ1wwkMmUUZiWLE1ZqmhZcKVgymuZqXQKlKkKJOcyhaIcFrlKaJUO67KQjJc1ZDvRyxvdVWO96O_JC8o5TTml2RCJ8Q1RWbkQK6eX0l0JK7W4Nlg3E9IFrRoQGFDVOWdVLjmDrCqKrCzSDFipMBpXqPWhj9ZOl1ApvCAnmzXR9RWj52JmLwTjecJpggJvegFnf7Tgg1hqr_CqpAHbdnnnPMfEOUX01T304d311EziBrSpLcZVnajYZSzjSclx2IkGD1D4VLDUCou61mhfc3i75oBMgJ9hJlvvxfjk-P_Zo-_r7Os77BxkE-beNm1Xbn4dfHH3pP8c8W03IfD-BlBYgt5BLZQO12WLW9ONoInoWvf20ETXuqJvXXRm95xv9f_q9hsXSkty |
| CitedBy_id | crossref_primary_10_1007_s40266_019_00640_5 crossref_primary_10_1038_s41598_022_10938_x crossref_primary_10_1111_bcp_15276 crossref_primary_10_1007_s00280_024_04666_4 crossref_primary_10_1016_j_lungcan_2016_05_020 crossref_primary_10_1371_journal_pone_0167923 crossref_primary_10_3390_cancers12040998 crossref_primary_10_1177_03008916211025091 crossref_primary_10_1371_journal_pone_0178676 crossref_primary_10_2147_OTT_S387165 crossref_primary_10_1016_j_ptdy_2018_06_006 crossref_primary_10_1186_s40780_022_00258_7 crossref_primary_10_1155_2022_3102641 crossref_primary_10_1016_j_cllc_2017_05_010 crossref_primary_10_3389_fphar_2022_796538 crossref_primary_10_1007_s15015_017_3111_7 crossref_primary_10_1097_MD_0000000000031770 crossref_primary_10_1200_PO_21_00312 crossref_primary_10_3390_jpm11050424 crossref_primary_10_2174_1574886317666220324100356 |
| Cites_doi | 10.1016/S1470-2045(14)71173-8 10.1158/1078-0432.1167.11.3 10.1016/j.lungcan.2013.06.008 10.1007/s40262-013-0058-5 10.1158/0008-5472.CAN-04-2818 10.1097/JTO.0b013e31822adaf7 10.1007/s00280-012-1929-4 10.1371/journal.pone.0136252 10.1371/journal.pone.0135393 10.1038/clpt.2012.73 10.1097/JTO.0b013e31829ceba4 10.1073/pnas.0405220101 10.1097/JTO.0b013e3181e2138b 10.1016/j.cllc.2014.07.005 10.1016/j.ejca.2008.10.026 10.1158/1078-0432.CCR-10-1588 10.3816/CLC.2005.n.030 10.1093/annonc/mdt012 10.1378/chest.06-1673 10.1016/j.cllc.2011.03.006 10.3892/mco.2013.190 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2016 Public Library of Science 2016 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2016 Chen et al 2016 Chen et al |
| Copyright_xml | – notice: COPYRIGHT 2016 Public Library of Science – notice: 2016 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2016 Chen et al 2016 Chen et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0149722 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Complete (ProQuest Database) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing and Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine |
| DocumentTitleAlternate | Antacid Use and De Novo Brain Metastases in EGFR-Mutant NSCLC Patients Treated Using EGFR-TKIs |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1771271135 oai_doaj_org_article_c2bcf674d6a74e3d8839823e49c4797c PMC4760710 3974012651 A443709744 26894507 10_1371_journal_pone_0149722 |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI RC3 7X8 5PM PUEGO AAPBV ABPTK |
| ID | FETCH-LOGICAL-c692t-84ea0b41eb942242c1987cceb7fa3c2be14cdea77a2e89586c01d25f98a479fe3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Oct 01 00:11:45 EDT 2023 Wed Aug 27 01:14:38 EDT 2025 Thu Aug 21 13:56:28 EDT 2025 Fri Jul 11 16:15:20 EDT 2025 Fri Jul 25 11:28:49 EDT 2025 Tue Jun 17 21:26:04 EDT 2025 Tue Jun 10 20:43:39 EDT 2025 Fri Jun 27 03:57:50 EDT 2025 Fri Jun 27 04:36:11 EDT 2025 Thu May 22 21:21:07 EDT 2025 Mon Jul 21 06:02:23 EDT 2025 Tue Jul 01 02:34:01 EDT 2025 Thu Apr 24 22:55:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-84ea0b41eb942242c1987cceb7fa3c2be14cdea77a2e89586c01d25f98a479fe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have declared that no competing interests exist. Conceived and designed the experiments: YMC CHL H-C. Chang TYC CCT WFF MCL. Performed the experiments: YMC. Analyzed the data: YMC CCW YHC. Contributed reagents/materials/analysis tools: YMC YHW MCS KTH SFL. Wrote the paper: YMC H-C. Chen YCC. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0149722 |
| PMID | 26894507 |
| PQID | 1771271135 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1771271135 doaj_primary_oai_doaj_org_article_c2bcf674d6a74e3d8839823e49c4797c pubmedcentral_primary_oai_pubmedcentral_nih_gov_4760710 proquest_miscellaneous_1767627171 proquest_journals_1771271135 gale_infotracmisc_A443709744 gale_infotracacademiconefile_A443709744 gale_incontextgauss_ISR_A443709744 gale_incontextgauss_IOV_A443709744 gale_healthsolutions_A443709744 pubmed_primary_26894507 crossref_citationtrail_10_1371_journal_pone_0149722 crossref_primary_10_1371_journal_pone_0149722 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-02-19 |
| PublicationDateYYYYMMDD | 2016-02-19 |
| PublicationDate_xml | – month: 02 year: 2016 text: 2016-02-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2016 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | SJ Henley (ref1) 2014; 63 JF Hilton (ref13) 2013; 82 S Thongprasert (ref9) 2011; 6 G Chen (ref8) 2013; 24 Y Togashi (ref17) 2010; 5 M Tokumo (ref6) 2005; 11 Y Togashi (ref15) 2012; 70 A Gurpide (ref18) 2005; 7 CH Lie (ref3) 2011; 12 W Pao (ref5) 2004; 101 A Horiike (ref19) 2007; 131 BY Wang (ref2) 2013; 8 T Kosaka (ref7) 2004; 64 MP Chu (ref12) 2015; 16 Y Kogure (ref4) 2015; 10 YM Chen (ref20) 2015; 10 Y Deng (ref14) 2014; 2 NR Budha (ref11) 2012; 92 M Fukudo (ref16) 2013; 52 S Heon (ref22) 2010; 16 EA Eisenhauer (ref21) 2009; 45 JC Yang (ref10) 2015; 16 22011650 - J Thorac Oncol. 2011 Nov;6(11):1872-80 26262682 - PLoS One. 2015;10(8):e0135393 15709185 - Clin Cancer Res. 2005 Feb 1;11(3):1167-73 22806307 - Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405 16179102 - Clin Lung Cancer. 2005 Sep;7(2):138-40 23910908 - Lung Cancer. 2013 Oct;82(1):136-42 23945383 - J Thorac Oncol. 2013 Sep;8(9):1128-35 24402465 - MMWR Morb Mortal Wkly Rep. 2014 Jan 10;63(1):1-5 22739140 - Clin Pharmacol Ther. 2012 Aug;92(2):203-13 24649318 - Mol Clin Oncol. 2014 Jan;2(1):116-120 15329413 - Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 20479691 - J Thorac Oncol. 2010 Jul;5(7):950-5 21550558 - Clin Lung Cancer. 2011 Mar;12(2):116-24 23532985 - Clin Pharmacokinet. 2013 Jul;52(7):593-609 15604253 - Cancer Res. 2004 Dec 15;64(24):8919-23 25589191 - Lancet Oncol. 2015 Feb;16(2):141-51 25246385 - Clin Lung Cancer. 2015 Jan;16(1):33-9 17565015 - Chest. 2007 Jun;131(6):1628-34 26313661 - PLoS One. 2015;10(8):e0136252 23456778 - Ann Oncol. 2013 Jun;24(6):1615-22 21030498 - Clin Cancer Res. 2010 Dec 1;16(23):5873-82 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 |
| References_xml | – volume: 16 start-page: 141 issue: 2 year: 2015 ident: ref10 article-title: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials publication-title: The Lancet Oncology doi: 10.1016/S1470-2045(14)71173-8 – volume: 11 start-page: 1167 issue: 3 year: 2005 ident: ref6 article-title: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.1167.11.3 – volume: 82 start-page: 136 issue: 1 year: 2013 ident: ref13 article-title: An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib publication-title: Lung cancer doi: 10.1016/j.lungcan.2013.06.008 – volume: 52 start-page: 593 issue: 7 year: 2013 ident: ref16 article-title: Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer publication-title: Clinical pharmacokinetics doi: 10.1007/s40262-013-0058-5 – volume: 64 start-page: 8919 issue: 24 year: 2004 ident: ref7 article-title: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications publication-title: Cancer research doi: 10.1158/0008-5472.CAN-04-2818 – volume: 6 start-page: 1872 issue: 11 year: 2011 ident: ref9 article-title: Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer doi: 10.1097/JTO.0b013e31822adaf7 – volume: 70 start-page: 399 issue: 3 year: 2012 ident: ref15 article-title: Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer publication-title: Cancer chemotherapy and pharmacology doi: 10.1007/s00280-012-1929-4 – volume: 10 start-page: e0136252 issue: 8 year: 2015 ident: ref20 article-title: Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors publication-title: PloS one doi: 10.1371/journal.pone.0136252 – volume: 10 start-page: e0135393 issue: 8 year: 2015 ident: ref4 article-title: Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations publication-title: PloS one doi: 10.1371/journal.pone.0135393 – volume: 92 start-page: 203 issue: 2 year: 2012 ident: ref11 article-title: Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? publication-title: Clinical pharmacology and therapeutics doi: 10.1038/clpt.2012.73 – volume: 8 start-page: 1128 issue: 9 year: 2013 ident: ref2 article-title: Lung cancer and prognosis in taiwan: a population-based cancer registry publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer doi: 10.1097/JTO.0b013e31829ceba4 – volume: 101 start-page: 13306 issue: 36 year: 2004 ident: ref5 article-title: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib publication-title: Proceedings of the National Academy of Sciences of the United States of America doi: 10.1073/pnas.0405220101 – volume: 5 start-page: 950 issue: 7 year: 2010 ident: ref17 article-title: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer doi: 10.1097/JTO.0b013e3181e2138b – volume: 63 start-page: 1 issue: 1 year: 2014 ident: ref1 article-title: Lung cancer incidence trends among men and women—United States, 2005–2009 publication-title: MMWR Morbidity and mortality weekly report – volume: 16 start-page: 33 issue: 1 year: 2015 ident: ref12 article-title: Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer publication-title: Clinical lung cancer doi: 10.1016/j.cllc.2014.07.005 – volume: 45 start-page: 228 issue: 2 year: 2009 ident: ref21 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: European journal of cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 16 start-page: 5873 issue: 23 year: 2010 ident: ref22 article-title: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib publication-title: Clinical cancer research: an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-10-1588 – volume: 7 start-page: 138 issue: 2 year: 2005 ident: ref18 article-title: Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature publication-title: Clinical lung cancer doi: 10.3816/CLC.2005.n.030 – volume: 24 start-page: 1615 issue: 6 year: 2013 ident: ref8 article-title: Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) publication-title: Annals of oncology: official journal of the European Society for Medical Oncology / ESMO doi: 10.1093/annonc/mdt012 – volume: 131 start-page: 1628 issue: 6 year: 2007 ident: ref19 article-title: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer publication-title: Chest doi: 10.1378/chest.06-1673 – volume: 12 start-page: 116 issue: 2 year: 2011 ident: ref3 article-title: First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan publication-title: Clinical lung cancer doi: 10.1016/j.cllc.2011.03.006 – volume: 2 start-page: 116 issue: 1 year: 2014 ident: ref14 article-title: The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer publication-title: Molecular and clinical oncology doi: 10.3892/mco.2013.190 – reference: 21550558 - Clin Lung Cancer. 2011 Mar;12(2):116-24 – reference: 20479691 - J Thorac Oncol. 2010 Jul;5(7):950-5 – reference: 25246385 - Clin Lung Cancer. 2015 Jan;16(1):33-9 – reference: 24402465 - MMWR Morb Mortal Wkly Rep. 2014 Jan 10;63(1):1-5 – reference: 26262682 - PLoS One. 2015;10(8):e0135393 – reference: 22011650 - J Thorac Oncol. 2011 Nov;6(11):1872-80 – reference: 15329413 - Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 – reference: 23456778 - Ann Oncol. 2013 Jun;24(6):1615-22 – reference: 15709185 - Clin Cancer Res. 2005 Feb 1;11(3):1167-73 – reference: 15604253 - Cancer Res. 2004 Dec 15;64(24):8919-23 – reference: 22739140 - Clin Pharmacol Ther. 2012 Aug;92(2):203-13 – reference: 25589191 - Lancet Oncol. 2015 Feb;16(2):141-51 – reference: 16179102 - Clin Lung Cancer. 2005 Sep;7(2):138-40 – reference: 24649318 - Mol Clin Oncol. 2014 Jan;2(1):116-120 – reference: 23945383 - J Thorac Oncol. 2013 Sep;8(9):1128-35 – reference: 23910908 - Lung Cancer. 2013 Oct;82(1):136-42 – reference: 17565015 - Chest. 2007 Jun;131(6):1628-34 – reference: 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 – reference: 21030498 - Clin Cancer Res. 2010 Dec 1;16(23):5873-82 – reference: 23532985 - Clin Pharmacokinet. 2013 Jul;52(7):593-609 – reference: 22806307 - Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405 – reference: 26313661 - PLoS One. 2015;10(8):e0136252 |
| SSID | ssj0053866 |
| Score | 2.3018234 |
| Snippet | Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it... Background Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs),... Background Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs),... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0149722 |
| SubjectTerms | Aged Antacids Antacids - therapeutic use Antineoplastic Agents - therapeutic use Biology and Life Sciences Biopsy Brain Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - secondary Brain research Cancer Cancer metastasis Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Cerebrospinal fluid Chemotherapy Complications and side effects Critical care Development and progression Dosage and administration Drug interaction Drug Interactions Epidermal growth factor Epidermal growth factor receptors Female Hospitals Humans Inhibitors Internal medicine Liver Lung cancer Lung diseases Male Medical prognosis Medical research Medicine Medicine and Health Sciences Metastases Metastasis Mutation Nervous system Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Physicians Prognosis Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase receptors Proton pump inhibitors Receptor, Epidermal Growth Factor - antagonists & inhibitors Research and Analysis Methods Retrospective Studies Risk factors Survival Tyrosine |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hnrggyquhARaEBBzcZu31rn1MQ0MLpCCa0N6s9XpMLEV2FCdI_Gb-BDO2Y9WoUjhwiRzv2N7Me5zdbxh7nRgVqAASJ8X450hIU8cobZyBRxtGpJv4ljYKTy7U2Ux-vPavb7T6ojVhNTxwzbhj68Y2VVomymgJXhJgRA9cD2RopQ61Je-LMW9bTNU-GK1YqWajnKfFcSOXo2WRwxEVBdp1O4GowutvvfLeclGUt6Wcf6-cvBGKxvfZvSaH5MN67vvsDuQP2H5jpSV_20BJv3vIfg_ztbFZwmclcJMn_D3wi-JnwU-oMwSfwNpgdljiRfjtaw2xWnJ6N8tPqXUseu0F_4CVOp4YV515OOaZsMQDZ7KhBsR4u9y5RLIFHwF-fEbnwUekSit-NS_4FayATykzBZoFBko-zjDjdLAIhuawni9pyM6n8ukv5CZd-inLceL8PJ9ncUYtgx6x2fh0OjpzmvYOjlWhu3YCCWYQSwFxKDGRcC29_7AWYp0aD8UOQtoEjNbGhSD0A2UHInH9NAwMSj4F7zHby1GgB4z7pGQeiNS1HiqJb4TUiVDGpLEfgPV7zNvKOrIN9jm14FhE1R96GmugWnQRaUjUaEiPOe1Vyxr7Ywf9CalRS0vI3dUJ1Oeo0edolz732AtSwqjeBtv6n2gopacHWP3JHntVURB6R07Lg36YTVlG51--_wPR5bcO0ZuGKC2QHdY0WzLwNxEqWIey36FEH2Q7wwdkMluulJHQWrhaCA9Z39-a0e3DL9thuikt-cuh2BCNwkCthRY99qS2upazrgpCiZVMj-mOPXZY3x3Js3kFni41ISoOnv4PWR2yu5g_V4v4Rdhne-vVBp5hjrqOn1fu6A_XV5SQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9Mw0IIhIV4QGx8rDDAICXjIVieOnTyhrqzbgA7E1m1vkeNctkpVUpoWid_Mn-AucQtBE-MlSuJz4o_7tM93jL3KjIpUBJmXo_zzJOS5Z5Q2XjegAyPSz0JLB4WHR-pgJD-ch-duwa1ybpVLnlgz6qy0tEa-I7QWvhYiCN9Nv3mUNYp2V10KjZvslkBJQy5d0WB_yYmRlpVyx-UCLXbc7GxPywK2yTTQvt8SR3XU_hVvXptOyuoqxfNv_8k_BNLgHrvrNEnea6Z-nd2AYoPdHrq98g227si24m9cbOm399nPXjE3dpzxUQXcFBl_D_yo_F7yXUoVwYcwN6guVlgJn740MVcrTou1fI9yySIbn_B9NN3xxaBO1cNR8YQp3njDBWUkxs8V3jGCTXgf8PIJuQnvE27N-Nllyc9gBvyEVFWgVqDk5IMxqqAeWsXgbpv2Espc-1d-8gMHlqp-HBfYcH5YXI7TMeUQesBGg72T_oHn8j14VsX-3IskmG4qBaSxRM3Ct7QgYi2kOjeB9VMQ0mZgtDY-RHEYKdsVmR_mcWSkjnMIHrK1Aud2k_GQsC4Akfs2kBCERkidCWVMnoYR2LDDguW0J9YFQ6ecHJOk3uHTaBQ1s5gQsiQOWTrMW9WaNsFAroHfJYxawVIo7_pFObtIHGdIsGM2V1pmymhsahahyhr5AcjYYq-07bDnhI9Jcy52xZCSnpSB7qI5KDvsZQ1B4TwK8he6MIuqSg4_n_4H0PHXFtBrB5SXOBzWuDMa2CcKE9aC3GpBIlOyreJNop7lqFTJb_LFmkuKurr4xaqYPko-gAWUC4JRKLm10KLDHjUEuBpZX0WxRNOmw3SLNFtD3y4pxpd1NHWpKcRi9_G_m_WE3UFVufbXF_EWW5vPFvAU1dF5-qzmOb8AyqmPSQ priority: 102 providerName: ProQuest |
| Title | Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26894507 https://www.proquest.com/docview/1771271135 https://www.proquest.com/docview/1767627171 https://pubmed.ncbi.nlm.nih.gov/PMC4760710 https://doaj.org/article/c2bcf674d6a74e3d8839823e49c4797c http://dx.doi.org/10.1371/journal.pone.0149722 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9Mw0BrdCy-I8bXCKAYhAQ-Z6sSJkweEtrJuA1qmrd32FjnOZa1UJaVpEfvN_AnukjQiaGh7idL47Nrn-_THHWNvY-35ng-xlaD-syQkiaU9pa2uQxdGpB27hi4KD4be0Vh-uXQvN9g6Z2uFwPxG147ySY0Xs91fP64_IcN_LLI2KLGutDvPUtglk1_ZKJQ3UTcpymkwkPW-AnJ3sXtJVovl2V2nukz3v1YayqqI6V9L7tZ8luU3maX_nq78S131H7IHlZ3J90rC2GIbkD5iWxUn5_x9FW76w2P2ey9dajON-TgHrtOYfwY-zH5mfJ-yR_ABLDVakDlWwl8nZRjWnNP6LT-g9LIo2Wf8EL15_NAvsvdwtEVhji_WYEVJirG51DpDsBnvAT6-oYDhPSK3Bb-YZPwCFsBHZL0C9QKVKe9P0Sq10FGG6rXsL1HRrf_KR9eITar6dZpix_lxOplGU0or9ISN-wej3pFVpYCwjBfYS8uXoLuRFBAFEo0N29AaiTEQqUQ7xo5ASBODVkrb4Aeu75muiG03CXwtVZCA85S1UpzQbcZdIkQHRGIbR4LjaiFVLDytk8j1wbht5qznOjRVfHRK0zELi00_hX5SOXUhUUhYUUibWXWteRkf5Bb4fSKjGpaiexcfssVVWAmLEAdmEk_J2NMKuxr7aMX6tgMyMDgqZdrsFRFhWF6VrWVUuCelo7roIco2e1NAUISPlI4QXelVnofH38_vAHR22gB6VwElGaLD6OraBo6JIoc1IHcakCinTKN4m1hmjZU8FEoJWwnhIOp31mx0c_HrupgapWOBKWQrgvFQmSuhRJs9K7muxqzt-YFEb6fNVIMfG6hvlqTTSRFgXSqKuth9fhf8vGD30YYuDvKLYIe1losVvEQ7dRl12D11qfDp9wQ9-4cdtrl_MDw57RQrP51CNP0BPxqa_A |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkIAXxMafFQYzCAQ8ZKsdJ04eENq_bmXrQKxjewuO42yVqqQ0LdO-FF-ML8Fd4hSCJsbLXqo0PjuOff7dXey7I-RlovzAD0zipCD_HGHS1FG-VE7bRYcRwRNPo6Nw78DfPRIfTryTOfKj9oXBY5U1JpZAneQav5GvMSkZl4y53vvRNwezRuHuap1Co2KLPXNxDiZb8a67BfP7ivPOdn9z17FZBRzth3ziBMKodiyYiUMB8otrNLu1NrFMlat5bJjQiVFSKm6C0At83WYJ99IwUEKGqXGh3RvkpnBBkqNnemenRn7ADt-37nmuZGuWG1ZHeWZW0RSRnDfEX5klYCYL5kfDvLhM0f37vOYfArBzj9y1mitdr1htgcyZbJHc6tm9-UWyYGGioG9sLOu398nP9Wyi9CChR4WhKkvolqEH-fecbmBqCtozEwXqaQGV4N-nKsZrQfHjMN3G3LUgNoZ0Z5yfw41OmRqIgqJrRnDh9KaYARmay5xDIBvSTQM_-4BedBN5eUyPz3J6bMaG9lE1NtgLkNS0MwCV1wEr3NjLqr_Iolc-lfYvYGCx6t4gg47TbnY2iAeYs-gBOboWTnhI5jOY2yVCPeRy17CUa1cY11NMyIT5SqWxFxjttYhbT3ukbfB1zAEyjModRQlGWDWLETJLZJmlRZxZrVEVfOQK-g3kqBkthg4vb-Tj08giUQQvplNfisRXErqaBKAiB9w1ItTwVlK3yAryY1T54c4AMFoXwpVtMD9Fi7woKTB8SIbnk07VtCii7scv_0F0-LlB9NoSpTkMh1bWJwTeCcOSNSiXG5QAgrpRvISrpx6VIvoNF1CzXlGXFz-fFWOjeOYwM_kUaXzQFCSTrEUeVQtwNrLcD0IBplSLyMbSbAx9syQbnJXR24XEkI7tx__u1gq5vdvv7Uf73YO9J-QOqOmlrwALl8n8ZDw1T0EVnsTPSvyh5Ot1A94vOoPNMw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkCZeEBt_VhjMIBDwkK12nDh5QGjrVla2joltbG_BcZytUpWUpmXaV-Mr8SW4S9xA0MR42UuVxmfHsc-_u4t9d4S8TJQf-IFJnBTknyNMmjrKl8ppu-gwInjiaXQU7u_7O8fi46l3Okd-zHxh8FjlDBNLoE5yjd_I15mUjEvGXG89tcciDra670ffHMwghTuts3QaFYvsmssLMN-Kd70tmOtXnHe3jzo7js0w4Gg_5BMnEEa1Y8FMHAqQZVyjCa61iWWqXM1jw4ROjJJScROEXuDrNku4l4aBEjJMjQvt3iK3pSsDXGNBpz5eAjji-9ZVz5Vs3XLG2ijPzBqaJZLzhigsMwbUcmF-NMyLq5Tev89u_iEMu_fIXavF0o2K7RbJnMmWyELf7tMvkUULGQV9Y-Nav71Pfm5kE6UHCT0uDFVZQrcM3c-_53QT01TQvpkoUFULqAT_Dqp4rwXFD8V0G_PYgggZ0g_j_AJudMs0QRSUXjOCC6c_xWzI0FzmHALZkHYM_OwBktEO8vWYnpzn9MSMDT1CNdlgL0Bq0-4A1F8HLHJjL6v-Irte-1R6dAkDi1V3Bxl0nPay80E8wPxFD8jxjXDCQzKfwdwuE-ohx7uGpVy7wrieYkImzFcqjb3AaK9F3Nm0R9oGYsd8IMOo3F2UYJBVsxghs0SWWVrEqWuNqkAk19BvIkfVtBhGvLyRj88ii0oRvJhOfSkSX0noahKAuhxw14hQw1tJ3SKryI9R5ZNbg2G0IYQr22CKihZ5UVJgKJEMF-WZmhZF1Pv05T-IDj83iF5bojSH4dDK-ofAO2GIsgblSoMSAFE3ipdx9cxGpYh-QwfUnK2oq4uf18XYKJ4_zEw-RRoftAbJJGuRR9UCrEeW-0EowKxqEdlYmo2hb5Zkg_MykruQGN6x_fjf3VolCwB10V5vf_cJuQMae-k2wMIVMj8ZT81T0Ion8bMSfij5etN49wsiF9E0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antacid+Use+and+De+Novo+Brain+Metastases+in+Patients+with+Epidermal+Growth+Factor+Receptor-Mutant+Non-Small+Cell+Lung+Cancer+Who+Were+Treated+Using+First-Line+First-Generation+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors&rft.jtitle=PloS+one&rft.au=Chen%2C+Yu-Mu&rft.au=Lai%2C+Chien-Hao&rft.au=Chang%2C+Huang-Chih&rft.au=Chao%2C+Tung-Ying&rft.date=2016-02-19&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=11&rft.issue=2&rft_id=info:doi/10.1371%2Fjournal.pone.0149722&rft.externalDBID=ISR&rft.externalDocID=A443709744 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |